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Natural productsNeural mechanisms underlying the onset and maintenance of epileptic seizures involve alterations in
inhibitory and/or excitatory neurotransmitter pathways. Thus, the prospecting of novel molecules from
natural products that target both inhibition and excitation systems has deserved interest in the rational
design of new anticonvulsants. We isolated the alkaloids (+)-erythravine and (+)-11-α-hydroxy-
erythravine from the ﬂowers of Erythrina mulungu and evaluated the action of these compounds against
chemically induced seizures in rats. Our results showed that the administration of different doses of (+)-
erythravine inhibited seizures evoked by bicuculline, pentylenetetrazole, and kainic acid at maximum of 80,
100, and 100%, respectively, whereas different doses of (+)-11-α-hydroxy-erythravine inhibited seizures at a
maximum of 100%when induced by bicuculline, NMDA, and kainic acid, and, to a lesser extent, PTZ (60%). The
analysis of mean latency to seizure onset of nonprotected animals, for speciﬁc doses of alkaloids, showed that
(+)-erythravine increased latencies to seizures induced by bicuculline. Although (+)-erythravine exhibited
very weak anticonvulsant action against seizures induced by NMDA, this alkaloid increased the latency in this
assay. The increase in latency to onset of seizures promoted by (+)-11-α-hydroxy-erythravine reached a
maximum of threefold in the bicuculline test. All animals were protected against death when treated with
different doses of (+)-11-α-hydroxy-erythravine in the tests using the four chemical convulsants. Identical
results were obtained when using (+)-erythravine in the tests of bicuculline, NMDA, and PTZ, and, to a lesser
extent, kainic acid. Therefore, these data validate the anticonvulsant properties of the tested alkaloids, which
is of relevance in consideration of the ethnopharmacological/biotechnological potential of E. mulungu.. Costábile Romano, 2.201, Zip
naerp.br (R.O. Beleboni).
vier OA license.© 2010 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
Epilepsy is a set of chronic disorders that modify brain function
and are associated with the occurrence of sudden and unexpected
seizures of convulsive or nonconvulsive nature. Most epileptic
syndromes have particular neurophysiological and clinical character-
istics, the seizures being the result of abnormal, hyperactive, or
hypersynchronous neuronal discharges [1]. Moreover, neuronal
mechanisms underlying the onset and maintenance of the epilepsies
involve marked alterations in the balance between excitatory and
inhibitory neurotransmission pathways in the central nervous system
(CNS) [1,2].
In most cases, treatment of the epilepsies consists of maintaining
the patient seizure free with anticonvulsant drugs. These drugssuppress synaptic hyperactivation by acting on ion channels,
metabolic enzymes, or neurotransmitter transporters or receptors,
the latter involving chieﬂy GABA and/or glutamate [3]. Despite the
considerable number of antiepileptic drugs, there is a need for novel
medicines, as not all patients with epilepsy respond satisfactorily to
the usual treatments, and also because these drugs have side effects
such as cognitive impairment, sedation, teratogenesis, and hirsutism
with chronic use [4–7]. In light of these facts, the search for novel
anticonvulsant compounds of different chemical nature and the
modiﬁcation of the structure of traditional drugs may lead to the
generation of more effective and better tolerated drugs, as well as to a
better understanding of the mechanisms through which the brain
becomes epileptic [6].
Erythrina mulungu (Sin. Corallodendron mulungu (Martius) Kuntze,
Erythrina ﬂammea Herzog, Erythrina mulungu Mart. ex Benth.) is a
deciduous tree found mainly in Brazilian cerrados and other tropical
regions [8,9]. The ﬂowers, fruits, seeds, and bark are frequently used in
folk medicine because of their effects on the CNS; for example,
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effects are some of those actions validated by different experimental
models [8,10–12]. Indeed, experiments have pointed to the effective
anxiolytic activity of E.mulunguhydroalcoholic extract [13–15] and also
to its anticonvulsant effects against seizures induced by different
chemoconvulsants [16]. Chromatographic puriﬁcation of the E.mulungu
hydroalcoholic extract led to the identiﬁcation of some alkaloids
with effective anxiolytic activity, among which are (+)-erythravine
and (+)-11α-hydroxy-erythravine [17,18].
As anxiolytics may also function as antiepileptic drugs and based on
the popular use of E. mulungu as well as on previous reports pointing to
the anticonvulsant properties of the hydroalchoolic extract of this plant,
the aim of the present work was to investigate the anticonvulsant
properties of (+)-erythravine and (+)-11α-hydroxy-erythravine
alkaloids, analyzing their effectiveness in the blockade of seizures
induced in rats by two GABAergic antagonists, bicuculline and
pentylenetetrazole (PTZ), and two glutamatergic agonists, NMDA and
kainic acid.
2. Material and Methods
2.1. Chemicals
Most of the chemical agents, reagents, and solvents used in this
study were purchased from Sigma–Aldrich (USA) or Merck (USA),
unless otherwise speciﬁed. Diazepam, ketamine, and xylazine,
acquired from Germed (Brazil), Agener União (Brazil), and Hertape
Callier (Brazil), respectively, were injected in a ﬁnal volume of
0.3 mL (intraperitoneally). All reagents were of analytical grade.
(+)-Erythravine and (+)-11-α-hydroxy-erythravine were diluted
in saline solution before bioassay and administered in a total volume
of 1 μL (intracerebroventricularly).
2.2. Animals
Male Wistar rats (200–250 g) were acquired from animal housing
at the University of São Paulo in Ribeirão Preto-SP, Brazil. Animals
were maintained under controlled conditions of light (12-hour dark–
light cycle, lights on at 7:00 AM), temperature (25 °C), and humidity
(55%). This work was approved by the Ethics Committee for
Experimental Animals at UNAERP (006/08). Experimental procedures
were performed according to the rules in the Handbook of Animal
Experimentation and Care from the Brazilian Society of Neurosciences
and Behavior. Furthermore, all efforts were made to avoid unneces-
sary stress and pain for the animals.
2.3. Isolation and identiﬁcation of (+)-erythravine and
(+)-11α-hydroxy-erythravine from Erythrina mulungu Mart. Ex Benth.
Flowers from E. mulungu (5.0 kg) were collected in Rifaina, São
Paulo, Brazil (latitude 20°07'41.7'', longitude 47°281'54.5'', 1037-GPS).
Flowered branches were herborized according to the guide of the
Medicinal Plants Herbarium in UNAERP and labeled with a voucher
number (HPMU-1330).
Puriﬁcation procedures followed those described by Flausino and
colleagues [17]. Brieﬂy, freshﬂowersweremacerated in a 50 L solution
of ethanol:water (7:3, v/v). After 15 days, the extract was ﬁltered and
the solvent submitted to rotary evaporation. The aqueous extract was
lyophilized, resulting in 86.905 g of dry extract,whichwas dissolved in
a solution of acetic acid:water (10%, v/v) and submitted to liquid–
liquid extractionusing absolute chloroform(CHCl3). The organic phase
was separated and the solvent was evaporated, resulting in fraction 1
(F1). Next, ammonium hydroxide was added to the aqueous phase to
increase the pH to the range 9–10 and this solution was then
resubmitted to extraction with CHCl3. The organic phase was
separated and the organic solvent evaporated, resulting in fraction2 (F2). The remaining aqueous fraction was named F3. To identify the
active compounds and to check the grade of purity, these three
fractions were analyzed with thin-layer chromatography in silica
using CHCl3:MeOH (7:1, v/v) as the mobile phase and revelation with
the Dragendorff reagent.
Fraction 1 (5.6 mg) was applied to a chromatography column
(50×150 mm) containing silica (0.035–0.070 mm) as stationary
phase and CHCl3:MeOH (10:0 and 8:2, v/v) as mobile phase. At this
point, 169 fractions were eluted and grouped as follows: F1.1 (1–27,
0.738 g); F1.2 (26–39, 0.982 g); F1.3 (40–49, 0.401 g); F1.4 (50–73,
0.467 g); F1.5 (74–135, 230 g); F1.6 (136–157, 0.188 g); F1.7 (158–168,
0.029 g); and F1.8 (169, 0.515 g). Fractions F1.2 and F1.8 (1.497 g)
provided a novel pool fractionated in a chromatography column
(20×425 mm), using silica (0.035–0.070 mm) and CHCl3/MeOH
(9:1, 8:2, 7:3 and 6:4; v/v) as mobile phase, resulting in four fractions:
F.1.2/8.1, F.1.2/8.2, F.1.2/8.3 and F.1.2/8.4. Next, F1.2/8.2was applied to a
silica–ﬂuoroscein preparative plate (Merck, USA) for alkaloid isolation
using as solvents toluene, acetone, ethanol, and ammonium hydroxide
(45:45:7:3, v/v), resulting in the elution of (+)-erythravine (2.4 mg).
Fractionation of F2 was conducted using a preparative plate
(200×200 mm) and samples were eluted in CHCl3/MeOH (7:1; v/v),
resulting in the isolation of (+)-11-α-hydroxy-erythravine (15.2 mg).
Isolated compounds were checked for grade of purity using
nuclear magnetic resonance (Varian Inc., USA) with scans at
500 MHz and tetramethylsilate as internal marker and deuterated
chloroform (CD-CHCl3) as solvent.
2.4. Surgery
Stainless-steel guide cannulas (0.7×10 mm) were implanted in
animals (n=6–8, each group) on anesthesia with ketamine and
xylazine (60 and 8 mg/kg, ip, respectively). Animals were placed in a
stereotaxic device (Stoelting-Standard, USA) and received a local
injection of 2% lidocaine to expose the calvaria and place the guide
cannula in the right lateral ventricle. The coordinates used were
0.9 mmposterior to bregma, 1.6 mm lateral frommidline, and 3.4 mm
ventral from the surface of the skull according to Paxinos andWatson
[19]. The cannula was ﬁxed to the skull using dental acrylate and was
sealed with a stainless-steel wire to avoid obstruction. After the
surgery, animals received an injection of Flunixin meglumine anti-
inﬂammatory (1.1 mg/kp, im). The animals were then allowed to rest
for 5–7 days to recover from surgery.
2.5. Anticonvulsant screening
On theday of the experiments,with the aid of a digital infusion pump
(Insight, Brazil) connected toaHamilton syringe (10 μL) andan injection
cannula, each animal was microinjected intracerebroventricularly (icv)
with saline or each of the alkaloids in concentrations ranging from
0.25 to 3 μg/μL. Animals used as a positive control received diazepam
(2mg/kg, ip). After 10 minutes, chemoconvulsants were injected in
doses adjusted to induce seizures in 97% of animals (CD97), as follows:
bicuculline (0.9 μg/μL, icv), NMDA (17 μg/μL, icv), kainic acid (0.8 μg/μL,
icv), and PTZ (80 mg/kg, ip). Intracerebroventricular injections were
administered in a total volume of 1 μL over 1 minute, whereas
intraperitoneal injections were delivered in a volume of 0.3 mL.
Animals were observed for 30 minutes for the occurrence of
seizures, and latency to onset or death was recorded. Seizures were
classiﬁed using the limbic seizure scale [20] as follows: 0 = no
seizure; 1 = orofacial movements; 2 = head myoclonus; 3 =
hindlimb myoclonus; 4 = elevation; 5 = elevation and limbic fall;
6 = head and ear myoclonus; 7 = rotation, jumps, and vocalization;
8 = class 7 behaviors and hypertonus.
One day after the assays, animals were euthanized with an
overdose of thiopental (100 mg/kg, ip; Cristalia, Brazil) and then
injected with toluidine blue (1 μL, icv). Brains were removed, frozen,
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there was inaccurate placement (≅5%) were not considered in the
analysis.2.6. Data analysis
Number of animals protected against generalized chemically
induced tonic–clonic seizures was plotted in relation to each
concentration of the alkaloids used. These frequencies were then
compared using the χ2 test. Latency to seizure onset in animals not
fully protected by the alkaloids was analyzed using one-way analysis
of variance (ANOVA), followed by the Tukey post test. A P valueb0.05
was considered statistically signiﬁcant. Data were analyzed and ﬁtted
using the software Graph Prism (Version 4.0, GraphPad Software,
USA).3. Results
3.1. Isolation and identiﬁcation of alkaloids
Alkaloid puriﬁcation was effective in providing the appropriate
amount of alkaloids to perform bioassays. In this regard, we obtained
15.2 and2.4 mgof (+)-11-α-hydroxy-erythravineand (+)-erythravine,
respectively. The degree of purity for both alkaloids was conﬁrmed by
NMR spectra (see Appendix—Supplementary Material).Bicuculline
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Fig. 1. Percentages of animals protected against seizures induced with the chemoconvulsant
(D) kainic acid (0.8 μg/μL, icv) after intracerebroventricular microinjection of different dose3.2. Anticonvulsant screening
Data from anticonvulsant screening of (+)-erythravine for
protecting animals against seizures are summarized in Fig. 1.
The data indicate that intracerebroventricular microinjection of
(+)-erythravine into rats prior to the administration of bicuculline
inhibited seizures in 40, 60, and 80% of animals at doses of 1, 2, and
3 μg/μL, respectively (χ2[3]=10.40, P=0.015) (Fig. 1A). In the NMDA
assay, treatment with (+)-erythravine at 3 μg/μL (icv) blocked
seizures in only 20% of animals (χ2[3]=3.158, P=0.3679) (Fig. 1B).
Systemic administration of PTZ (80 mg/kg, ip) induced generalized
seizures in all injected animals, which were blocked by pre-
administration of (+)-erythravine in 60 and 100% of animals at
doses of 1 and 2 or 3 μg/μL, respectively (χ2[3]=14.73, P=0.0021)
(Fig. 1C). In the kainic acid assay, pretreatment of animals with
(+)-erythravine inhibited seizures in 40 and 100% of animals at
doses of 1 and 2 or 3 μg/μL, respectively (χ2[4]=20.19, P=0.0005);
0.5 μg/μL was not protective (Fig. 1D). The anticonvulsant activity of
(+)-erythravine exhibited a dose-dependent proﬁle in all experiments.
Data from anticonvulsant screening of (+)-11-α-erythravine
for protecting animals against seizures are illustrated in Fig. 2.
Our results show that this alkaloid, when centrally applied to rats
prior to the administration of bicuculline, inhibited seizures in all
animals at 1 and 2 μg/μL, and inhibited seizures in 60% of animals at
0.5 μg/μL. At 0.25 μg/μL, (+)-11-α-erythravine exhibited no anticon-
vulsant activity (χ2[4]=20.19, P=0.0005) (Fig. 2A). Tonic–clonic
seizures induced by the glutamatergic agonist NMDAwere blocked byNMDA
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Fig. 2. Percentages of animals protected against seizures induced with the chemoconvulsants (A) bicuculline (0.9 μg/μL, icv), (B) NMDA (17 μg/μL, icv), (C) PTZ (80 mg/kg, ip), and
(D) kainic acid (0.8 μg/μL, icv) after intracerebroventricular microinjection of different doses of (+)-11α-hydroxy-erythravine (0.12–3.0 μg/μL). *Pb0.05, **Pb0.01, ***Pb0.001.
Table 1
Mean latency to onset of seizures evoked by the administration of chemoconvulsants.
Latency to seizure onset (s)
Bicuculline PTZ NMDA Kainic acid
Saline 74.63±7.018 50.0±8.25 40.50±6.61 318±9.7
Diazepam NS NS NS NS
Erythravine
0.5 μg/μL NA NA NA 18±3.7a
1 μg/μL 140.0±52.92 165.0±5.0b 31.4±14.5 320±72
2 μg/μL 143.0±3.00 NS 138±14.7b NS
3 μg/μL 300c NS 218.8±16.6a NS
11-α-Hydroxy-
erythravine
0.25 μg/μL 94.0±10.42 NA 66.6±23.5 NA
0.5 μg/μL 244.5±8.5b NA 300c 100±33.7b
1 μg/μL NS 289.5±185.5 NS 136.7±22b
2 μg/μL NS 360±272.9 NS NS
3 μg/μL NA 269±31.0 NA NS
Note. Data represent means±SEM. NA, not applied; NS, no seizure.
a Pb0.001.
b Pb0.01.
c Refers to one seizing animal; therefore, statistical analysis did not include this
datum.
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100% of animals were protected from those seizures by the
administration of 1 and 2 μg/μL (+)-11-α-hydroxy-erythravine
(χ2[4]=21.75, P=0.0002) (Fig. 2B). Seizures induced by systemic
administration of PTZ were blocked by the pre-administration of
(+)-11-α-hydroxy-erythravine in only 40 and 60% of animals at 2
and 3 μg/μL, respectively (χ2[3]=7.200, P=0.0658) (Fig. 2C). In the
case of kainic acid, 40 and 100% of animals were protected at 1 and
2 μg/μL, respectively (χ2[3]=17.33, P=0.0006) (Fig. 2D). As observed
for (+)-erythravine, the anticonvulsant activity of (+)-11-α-hydroxy-
erythravine exhibited a dose-dependent proﬁle in all experiments.
In all experiments, microinjections of bicuculline (0.9 μg/μL, icv),
NMDA(17 μg/μL, icv), PTZ (80 mg/kg, ip), and kainic acid (0.8 μg/μL, icv)
induced tonic–clonic seizures in all animals pre-injected with saline.
Conversely, diazepam protected 100% of animals against seizures.
Analysis of mean latency to seizure onset in unprotected animals
for both alkaloids is summarized in Table 1.
With respect to unprotected animals treated with (+)-erythravine,
we observed an increase in latency to onset of seizures induced
with bicuculline, although this increase was not statistically signiﬁcant
(F[2,12]=3.486, P=0.07). Analysis of animals treatedwithPTZ showed
that at the only nonprotective dose (1 μg/μL), (+)-erythravine
increased the mean latency to onset compared with that of animals
injected with saline (t=9.014, P=0.0008). Although (+)-erythravine
showedveryweakanticonvulsant activity against seizures inducedwith
NMDA, in this assay, this alkaloid increased the latency to onset of
seizures at doses of 2 and 3 μg/μL (F[3,17]=38.4, Pb0.0001). Admin-
istration of (+)-erythravineat0.5 μg/μLbeforekainic aciddecreased the
latency to seizure onset as comparedwith that for animals injectedwith
(+)-erythravine 1 μg/μL as well as saline, pointing to a proconvulsant
effect at the lowest dose used (F[2,17]=38.4, Pb0.0001].
With respect to mean latency to seizure onset after treatment
with (+)-11-α-hydroxy-erythravine, our ﬁndings showed that thisalkaloid, at a dose of 0.5 μg/μL, increased the latency to onset of
seizures evoked with bicuculline relative to the group injected with
saline as well as the group injected with the lowest dose of the
alkaloid (0.25 μg/μL) (F[2,14]=55.46, Pb0.0001). The unprotected
animals administered PTZ after (+)-11-α-hydroxy-erythravine
exhibited seizures with heterogeneous latencies to seizure onset,
and thus we did not observe statistical differences among means in
these groups of animals (F[3,13]=0.6887, P=0.5814).When injected
before NMDA, (+)-11-α-hydroxy-erythravine 0.25 μg/μL did not
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administration of 0.5 μg/μL 11-α-hydroxy-erythravine induced a
sevenfold increase in the latency to seizure onset of the only
seizing animal. Regarding kainic acid-induced seizures, we observed
a signiﬁcant decrease in the latency to seizure onset in animals
treated with (+)-11-α-hydroxy-erythravine 0.5 and 1 μg/μL (F[2,12]=
23.76, Pb0.0001). These ﬁndings are similar to those obtained for
(+)-erythravine 0.5 μg/μL.
All animals were protected against death when treated with
different doses of (+)-11-α-hydroxy-erythravine before bicuculline,
NMDA, PTZ, and kainic acid. Identical results were obtained when
using (+)-erythravine in the tests of bicuculline, NMDA, and PTZ.
However, the protection against death afforded by (+)-erythravine
was 60, 80, and 100% at 0.5, 1, and 2 μg/μL (icv), respectively, in the
kainic acid test. Mortality was 100% in animals injected only with
saline before NMDA, PTZ, and kainic acid and 80% in animals injected
only with saline before bicuculline.
4. Discussion
According to the World Health Organization (WHO), from 65 to
80% of the world's population, partially or totally, depends on
nonconventional medicines for primary health care [21]. Plant
extracts have been used in traditional folk medicine for centuries in
the treatment of CNS disorders. With formalization of a pharma-
cological therapy approach, the pharmaceutical industry has tried to
isolate and design neuroactive drugs from natural probes present in
plants [22].
In Brazilian traditional medicine, E. mulungu extracts are commonly
used to treat anxiety and pain, as sedatives, and for blood pressure
control [8,10]. Scientiﬁc investigations have reported the neurobiolog-
ical activity, including anticonvulsant, anxiolytic, and analgesic proper-
ties, of the hydroalcoholic extract of parts of E. mulungu [12–16]. The
analgesic activity appears to be independent of opioidmechanisms [12],
and according to Vasconcelos and colleagues [16], the hydroalcoholic
extract of the stem bark from specimens of E. mulungu inhibits seizures
induced in mice by the administration of strychnine and PTZ.
Fractionation of E. mulungu extract revealed the presence of two
major alkaloids: (+)-11-α-hydroxy-erythravine and (+)-erythravine.
These alkaloids promote anxiolytic effects when administered to mice
submitted to a light–dark choice apparatus and elevated plus maze
[17,18].
Anxiety and epilepsy can be explained on the basis of similar
neurobiological concepts, involving, in particular, alterations in the
neurotransmitter balance in inhibitory and excitatory pathways. In
fact, some anxiolytic drugs also act as anticonvulsants, such as the
benzodiazepines. On the basis of the results presented, both anxiolytic
alkaloids exhibited signiﬁcant anticonvulsant activity against chem-
ically induced seizures in rats. However, with respect to blocking
generalized tonic–clonic seizures induced by two GABAergic antago-
nists, bicuculline and PTZ, and two glutamatergic agonists, NMDA and
kainic acid, (+)-erythravine and (+)-11α-hydroxy-erythravine did
not differ enough to predict a preferential action of these alkaloids on
inhibitory or excitatory pathways. It has been suggested that alkaloids
from Erythrina species act on the CNS by modifying GABA neurotrans-
mission. It should be pointed out that agonists of GABA/benzodiaze-
pine receptor typically promote motor impairment, particularly at
higher doses [18,23]. As suggested by Flausino and colleagues [18],
because the E. mulungu extract and (+)-erythravine/(+)-11-α-
hydroxy-erythravine did not cause motor disruptions in mice [11], it
is reasonable to assume that these alkaloids could be not active only by
a prevalent action onGABAneurotransmission. The characterization of
themodeof action of these erythrinian alkaloids is currently underway
in our laboratory.
Once again, as demonstrated by Vasconcelos and colleagues [11],
systemic administration of the E.mulunguhydroalcholic extract in dosesup to 400 mg/kg does not impair motor coordination in female mice
submitted to the rotarod test. Moreover, behavioral analysis of these
animals in the open ﬁeld pointed to a depressant effect on rearing
and other parameters of exploratory behavior, which, according to
the authors, could account for the sedative properties of the extract.
We thus could consider the extract well tolerated. The importance
of these data lies in the continuous need for novel and better tolerated
antiepileptic drugs as therapy for the epilepsies as well as other
syndromesof convulsive symptomatology [7]. As in theworkof Flausino
and colleagues [18], the alkaloids (+)-erythravine and (+)-11-α-
hydroxy-erythravine were orally administered to animals with result-
ing anxiolytic action; it is important to note that these alkaloids are
well absorbed in the gastrointestinal tract and may be able to cross the
blood–brain barrier, which is of relevance in the development of new
drugs acting on the CNS, including antiepileptic drugs.
This work validates oncemore the ethnopharmacological potential
of E. mulungu in the treatment of neurological disorders and also
complies with biotechnological implications, as E. mulungu extract has
been used in phytotherapeutic compositions/medicines in Brazil and
the United States. In this context, continuing investigation of the
mode of action of these alkaloids could lead to novel probes that could
be used in rational drug design, as well as tools in the investigation of
neural substrates that could be involved in the onset andmaintenance
of epileptic seizures.
Acknowledgments
The authors are grateful to FAPESP for Grants 08/52627-9 and 09/
11357-1 and to Mrs. Sarazetti Pereira and Karen Lanza Iamamura
(UNAERP) for technical assistance.
Appendix A. Supplementary data
Supplementary material associated with this article can be found,
in the online version, at doi:10.1016/j.yebeh.2010.12.037.
References
[1] Engel Jr J. Surgical treatment of the epilepsies. 2nd ed. New York: Raven Press;
1993.
[2] Delgado-Escueta AV, Wilson WA, Olsen RW, Porter RJ. New waves of research in
the epilepsies: crossing into the third millennium. In: Delgado-Escueta AV, Wilson
WA, Olsen RW, Porter RJ, editors. Jasper's basic mechanisms of the epilepsies.
Advances in Neurology. vol. 79, 3rd ed. Philadelphia: Lippincott Williams &
Wilkins; 1999.
[3] Bialer M, White HS. Key factors in the discovery and development of new
antiepileptic drugs. Nat Rev Drug Discovery 2010;9:68–82.
[4] Krogsgaard-Larsen P, Frolund BF, Falch E. Inhibitors of gamma-aminobutyric acid
transport as experimental tools and therapeutic agents. Meth Enzymol 1998;296:
165–75.
[5] Andersen KE, Lau J, Lundt BF, et al. Synthesis of novel GABA uptake inhibitors:
Part 6: Preparation and evaluation of N-omega asymmetrically substituted
nipecotic acid derivatives. Bioorg Med Chem 2001;9:2773–85.
[6] Perucca E. An introduction to antiepileptic drugs. Epilepsia 2005;46:31–7.
[7] Mortari MR, Cunha AO, Ferreira LB, dos Santos WF. Neurotoxins from
invertebrates as anticonvulsants: from basic research to therapeutic application.
Pharmacol Ther 2007;114:171–83.
[8] Lourenzi H. Árvores Brasileiras: Manual de Identiﬁcação e Cultivo de Plantas. São
Paulo: Plantarum; 1992.
[9] Neill DA. Experimental studies on species relationships in Erytrina (Leguminosae:
Papilionoidae). Ann Mo Bot Gard 1988;75:886–969.
[10] Rodrigues VEG, Carvalho DA, editors. Plantas Medicinais do Cerrado. Lavras:
Editora da Universidade Federal de Lavras; 2001.
[11] Vasconcelos SM, Macedo DS, De Melo CT, et al. Central activity of hydroalcoholic
extracts from Erythrina velutina and Erythrina mulungu in mice. J Pharm Pharmacol
2004;56:389–93.
[12] Vasconcelos SM, Rebouças OG, De Carvalho M, et al. Antinociceptive activities of
the hydroalcoholic extracts from Erythrina velutina and Erythrina mulungu in mice.
Biol Pharm Bull 2003;6:946–9.
[13] Onusic GM, Nogueira RL, Pereira AM, Viana MB. Effect of acute treatment with a
water–alcohol extract of Erythrina mulungu on anxiety-related responses in rats.
Braz J Med Biol Res 2002;35:473–8.
[14] Onusic GM, Nogueira RL, Pereira AM, Flausino Jr OA, Viana MDEB. Effects of
chronic treatment with a water–alcohol extract from Erythrina mulungu on
anxiety-related responses in rats. Biol Pharm Bull 2003;26:1538–42.
446 S.A. Faggion et al. / Epilepsy & Behavior 20 (2011) 441–446[15] Ribeiro MD, Onusic GM, Poltronieri SC, Viana MB. Effect of Erythrina velutina and
Erythrina mulungu in rats submitted to animal models of anxiety and depression.
Braz J Med Biol Res 2006;39:263–70.
[16] Vasconcelos SM, Lima NM, Sales GT, et al. Anticonvulsant activity of hydroalcoholic
extracts from Erythrina velutina and Erythrinamulungu. J Ethnopharmacol 2007;110:
271–4.
[17] Flausino JrOA, Santos LA,VerliH, PereiraAM,BolzaniVS,Nunes-De-SouzaRL.Anxiolytic
effects of erythrinian alkaloids from Erythrina mulungu. J Nat Prod 2007;70:48–53.
[18] Flausino Jr OA, Pereira AM, Bolzani VS, Nunes-De-Souza RL. Effects of erythrinian
alkaloids isolated from Erythrina mulungu (Papilionaceae) in mice submitted to
animal models of anxiety. Biol Pharm Bull 2007;30:375–8.[19] Paxinos G, Watson C. The rat brain in stereotaxic coordinates. 2nd ed. San Diego:
Academic Press; 1986.
[20] Pinel JP, Rovner LI. Electrode placement and kindling: induced experimental
epilepsy. Exp Neurol 1978;58:335–46.
[21] Akerele O. Nature's medicinal bounty: don't throw it away. World Health Forum
1993;14:390–5.
[22] Quintans Júnior LJ, Almeida JRGS, Lima JT, et al. Plants with anticonvulsant
properties: a review. Braz J Pharmacognosy 2008;18(Suppl):798–819.
[23] Garín-Aguilar ME, Luna JE, Soto-Hernández M, Valencia del Toro G, Vázquez MM.
Efect of crude extracts of Erythrina americana Mill. on aggressive behavior in rats.
J Ethnopharmacol 2000;69:189–96.
